{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:09:59Z","timestamp":1782216599443,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T00:00:00Z","timestamp":1253059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s10875-009-9326-4","type":"journal-article","created":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T07:51:15Z","timestamp":1253001075000},"page":"34-44","source":"Crossref","is-referenced-by-count":13,"title":["A New Model of Induced Experimental Systemic Lupus Erythematosus (SLE) in Pigs and Its Amelioration by Treatment with a Tolerogenic Peptide"],"prefix":"10.1007","volume":"30","author":[{"given":"Amir","family":"Sharabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidy","family":"Zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Mozes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,9,16]]},"reference":[{"key":"9326_CR1","first-page":"46","volume-title":"Dubious\u2019 lupus erythematosus","author":"BH Hahn","year":"2006","unstructured":"Hahn BH. Overview of pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubious\u2019 lupus erythematosus. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 46\u201353."},{"key":"9326_CR2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1615\/CritRevImmunol.v25.i2.30","volume":"25","author":"G Nagy","year":"2005","unstructured":"Nagy G, Koncz A, Perl A. T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol. 2005;25:123\u201340.","journal-title":"Crit Rev Immunol"},{"key":"9326_CR3","first-page":"121","volume-title":"Systemic lupus erythematosus","author":"A Theofilopoulos","year":"1992","unstructured":"Theofilopoulos A. Murine models of lupus. In: Lahita RG, editor. Systemic lupus erythematosus. New York: Churchill Livingston; 1992. p. 121\u201394."},{"key":"9326_CR4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1073\/pnas.85.7.2260","volume":"85","author":"S Mendlovic","year":"1988","unstructured":"Mendlovic S, Brocke S, Shoenfeld Y, Ben Basat M, Meshorer A, Bakimer R. Induction of a systemic lupus erythematosus like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A. 1988;85:2260\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9326_CR5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/intimm\/5.10.1293","volume":"5","author":"A Waisman","year":"1993","unstructured":"Waisman A, Mendlovic S, Ruiz JP, Zinger H, Meshorer A, Mozes E. The role of the 16\/6 idiotype network in the induction and manifestations of systemic lupus erythematosus. Int Immunol. 1993;5:1293\u2013300.","journal-title":"Int Immunol"},{"key":"9326_CR6","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/eji.1830230726","volume":"23","author":"A Waisman","year":"1993","unstructured":"Waisman A, Mozes E. Variable regions of autoantibodies isolated from mice with experimental systemic lupus erythematosus. Eur J Immunol. 1993;23:1566\u201373.","journal-title":"Eur J Immunol"},{"key":"9326_CR7","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1073\/pnas.94.9.4620","volume":"94","author":"A Waisman","year":"1997","unstructured":"Waisman A, Ruiz PJ, Israeli E, Eilat E, K\u02c6nen-Waisman S, Zinger H, et al. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci U S A. 1997;94:4620\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9326_CR8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1023\/A:1006663519132","volume":"20","author":"E Eilat","year":"2000","unstructured":"Eilat E, Zinger H, Nyska A, Mozes E. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol. 2000;20:268\u201378.","journal-title":"J Clin Immunol"},{"key":"9326_CR9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1073\/pnas.98.3.1148","volume":"98","author":"E Eilat","year":"2001","unstructured":"Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2001;98:1148\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9326_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/intimm\/dxg026","volume":"15","author":"H Zinger","year":"2003","unstructured":"Zinger H, Eilat E, Meshorer A, Mozes E. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZBxNZW)F1 mice via active suppression. Int Immunol. 2003;15:205\u201314.","journal-title":"Int Immunol"},{"key":"9326_CR11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/intimm\/7.4.689","volume":"7","author":"A Waisman","year":"1995","unstructured":"Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int Immunol. 1995;7:689\u201396.","journal-title":"Int Immunol"},{"key":"9326_CR12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10875-004-6245-2","volume":"24","author":"D Luger","year":"2004","unstructured":"Luger D, Dayan M, Zinger H, Liu J-P, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol. 2004;24:579\u201390.","journal-title":"J Clin Immunol"},{"key":"9326_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clim.2008.12.009","volume":"131","author":"R Parameswarran","year":"2009","unstructured":"Parameswarran R, Ben David H, Sharabi A, Zinger H, Mozes E. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. Clin Immunol. 2009;131:223\u201332.","journal-title":"Clin Immunol"},{"key":"9326_CR14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.clim.2005.09.003","volume":"117","author":"MJ Rapoport","year":"2005","unstructured":"Rapoport MJ, Sharabi A, Aharoni D, Bloch O, Zinger H, Dayan M, et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol. 2005;117:262\u201370.","journal-title":"Clin Immunol"},{"key":"9326_CR15","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.4049\/jimmunol.179.8.4979","volume":"179","author":"A Sharabi","year":"2007","unstructured":"Sharabi A, Luger D, Ben-David H, Dayan M, Zinger H, Mozes E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J Immunol. 2007;179:4979\u201387.","journal-title":"J Immunol"},{"key":"9326_CR16","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1073\/pnas.0603201103","volume":"103","author":"A Sharabi","year":"2006","unstructured":"Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-\u03b2. Proc Natl Acad Sci U S A. 2006;103:8810\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9326_CR17","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.4049\/jimmunol.181.5.3243","volume":"181","author":"A Sharabi","year":"2008","unstructured":"Sharabi A, Mozes E. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. J Immunol. 2008;181:3243\u201351.","journal-title":"J Immunol"},{"key":"9326_CR18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.2003.02058.x","volume":"131","author":"ZM Sthoeger","year":"2003","unstructured":"Sthoeger ZM, Dayan M, Tcherniack A, Green L, Toledo S, Segal R, et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol. 2003;131:385\u201392.","journal-title":"Clin Exp Immunol"},{"key":"9326_CR19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2249.2004.02559.x","volume":"137","author":"N Mauermann","year":"2004","unstructured":"Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol. 2004;137:513\u201320.","journal-title":"Clin Exp Immunol"},{"key":"9326_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.humimm.2009.01.018","volume":"70","author":"ZM Sthoeger","year":"2009","unstructured":"Sthoeger ZM, Sharabi A, Dayan M, Zinger H, Asher I, Sela U, et al. The tolerogenic peptide, hCDR1, down-regulates pathogenic cytokines and apoptosis and up-regulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol. 2009;70:139\u201345.","journal-title":"Hum Immunol"},{"key":"9326_CR21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1600-065X.2003.00081.x","volume":"196","author":"AD Kirk","year":"2003","unstructured":"Kirk AD. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev. 2003;196:176\u201396.","journal-title":"Immunol Rev"},{"key":"9326_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-2427(02)00045-4","volume":"87","author":"A Saalm\u00fcller","year":"2002","unstructured":"Saalm\u00fcller A, Werner T, Fachinger V. T-helper cells from naive to committed. Veterinary Immunol Immunopathol. 2002;87:137\u201345.","journal-title":"Veterinary Immunol Immunopathol"},{"key":"9326_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-1759(01)00511-7","volume":"259","author":"Rodr\u00ecguez-Carre\u00f2o","year":"2002","unstructured":"Rodr\u00ecguez-Carre\u00f2o, L\u00fbpez-Fuertes L, Revilla C, Ezquerra A, Alonso F, Dom\u00ecnguez J. Phenotypic characterization of porcine IFN-producing lymphocytes by flow cytometry. J Immunol Methods. 2002;259:171\u20139.","journal-title":"J Immunol Methods"},{"key":"9326_CR24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/keh688","volume":"44","author":"G Riemekasten","year":"2005","unstructured":"Riemekasten G, Hahn BH. Key autoantigens in SLE. Rheumatology. 2005;44:975\u201382.","journal-title":"Rheumatology"},{"key":"9326_CR25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.56.7.481","volume":"56","author":"CC Mok","year":"2003","unstructured":"Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56:481\u201390.","journal-title":"J Clin Pathol"},{"key":"9326_CR26","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3168::AID-IMMU3168>3.0.CO;2-H","volume":"29","author":"P Kuo","year":"1999","unstructured":"Kuo P, Bynoe MS, Wang C, Diamond B. Bcl-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. Eur J Immunol. 1999;29:3168\u201378.","journal-title":"Eur J Immunol"},{"key":"9326_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2567.1997.00122.x","volume":"90","author":"M Dayan","year":"1997","unstructured":"Dayan M, Zinger H, Kalush F, Mor G, Amir-Zaltzman Y, Kohen F, et al. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations. Immunology. 1997;90:101\u20138.","journal-title":"Immunology"},{"key":"9326_CR28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2249.1995.tb02278.x","volume":"101","author":"R Segal","year":"1995","unstructured":"Segal R, Dayan M, Zinger H, Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation. Clin Exp Immunol. 1995;101:66\u201372.","journal-title":"Clin Exp Immunol"},{"key":"9326_CR29","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.4049\/jimmunol.167.5.2452","volume":"167","author":"JP Seery","year":"2001","unstructured":"Seery JP, Cattell V, Watt FM. Cutting edge: amelioration of kidney disease in a transgenic mouse model of lupus nephritis by administration of the caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-(\u03b2-o-methyl)-flu-oromethylketone. J Immunol. 2001;167:2452\u20135.","journal-title":"J Immunol"},{"key":"9326_CR30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clim.2006.01.007","volume":"119","author":"A Sharabi","year":"2006","unstructured":"Sharabi A, Haviv A, Zinger H, Dayan M, Mozes E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin Immunol. 2006;119:146\u201355.","journal-title":"Clin Immunol"},{"key":"9326_CR31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF00197516","volume":"16","author":"DA Horwitz","year":"1994","unstructured":"Horwitz DA, Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol. 1994;16:181\u2013200.","journal-title":"Springer Semin Immunopathol"},{"issue":"Suppl 1","key":"9326_CR32","doi-asserted-by":"crossref","first-page":"I49","DOI":"10.1136\/ard.58.2008.i49","volume":"58","author":"AN Theofilopoulos","year":"1999","unstructured":"Theofilopoulos AN, Lawson BR. Tumour necrosis factor and other cytokines in murine lupus. Ann Rheum Dis. 1999;58(Suppl 1):I49\u201355.","journal-title":"Ann Rheum Dis"},{"key":"9326_CR33","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.4049\/jimmunol.158.6.3009","volume":"158","author":"R Segal","year":"1997","unstructured":"Segal R, Bermas BL, Dayan M, Kalush F, Shearer GM, Mozes E. Kinetics of cytokine production in experimental systemic lupus erythematosus: involvement of T helper cell 1\/T helper cell 2-type cytokines in disease. J Immunol. 1997;158:3009\u201316.","journal-title":"J Immunol"},{"key":"9326_CR34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/ard.59.4.243","volume":"59","author":"GS Dean","year":"2000","unstructured":"Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis. 2000;59:243\u201351.","journal-title":"Ann Rheum Dis"},{"key":"9326_CR35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clim.2004.04.007","volume":"112","author":"MJ Kaplan","year":"2004","unstructured":"Kaplan MJ. Apoptosis in systemic lupus erythematosus. Clin Immunol. 2004;112:210\u20138.","journal-title":"Clin Immunol"},{"key":"9326_CR36","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/eji.200323665","volume":"33","author":"H Tr\u00e9b\u00e9den-N\u00e8gre","year":"2003","unstructured":"Tr\u00e9b\u00e9den-N\u00e8gre H, Weill B, Fournier C, Batteux F. B cell apoptosis accelerates the onset of murine lupus. Eur J Immunol. 2003;33:1603\u201312.","journal-title":"Eur J Immunol"},{"key":"9326_CR37","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.4049\/jimmunol.152.7.3685","volume":"152","author":"W Emlen","year":"1994","unstructured":"Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994;152:3685\u201392.","journal-title":"J Immunol"},{"key":"9326_CR38","doi-asserted-by":"crossref","unstructured":"Ben-David H, Sharabi A, Parameswaran R, Zinger H, Mozes E. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of IL-7, leading to apoptosis. Immunology. 2009;doi: 10.1111\/j.1365-2567.2009.03109.x .","DOI":"10.1111\/j.1365-2567.2009.03109.x"},{"key":"9326_CR39","doi-asserted-by":"crossref","unstructured":"Sharabi A, Lapter S, Mozes E. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. J Autoimmun. 2009;doi: 10.1016\/j.jaut.2009.06.002 .","DOI":"10.1016\/j.jaut.2009.06.002"},{"key":"9326_CR40","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.4049\/jimmunol.160.5.2539","volume":"160","author":"K Ohtsuka","year":"1998","unstructured":"Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1998;160:2539\u201345.","journal-title":"J Immunol"},{"key":"9326_CR41","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1182\/blood.V87.4.1439.bloodjournal8741439","volume":"87","author":"L Yaswen","year":"1996","unstructured":"Yaswen L, Kulkarni AB, Fredrickson T, Mittleman B, Schiffman R, Payne S, et al. Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood. 1996;87:1439\u201345.","journal-title":"Blood"},{"key":"9326_CR42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","volume":"22","author":"S Sakaguchi","year":"2004","unstructured":"Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531\u201362.","journal-title":"Annu Rev Immunol"},{"key":"9326_CR43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.0105-2896.2005.00247.x","volume":"204","author":"S Paust","year":"2005","unstructured":"Paust S, Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev. 2005;204:195\u2013207.","journal-title":"Immunol Rev"},{"key":"9326_CR44","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/ar2511","volume":"10","author":"DA Horwitz","year":"2008","unstructured":"Horwitz DA. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther. 2008;10:227.","journal-title":"Arthritis Res Ther"},{"key":"9326_CR45","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2362.2007.01882.x","volume":"37","author":"SC Lin","year":"2007","unstructured":"Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH. The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. 2007;37:987\u201396.","journal-title":"Eur J Clin Invest"},{"key":"9326_CR46","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2567.2007.02565.x","volume":"121","author":"A Sharabi","year":"2007","unstructured":"Sharabi A, Azulai H, Sthoeger ZM, Mozes E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology. 2007;121:248\u201357.","journal-title":"Immunology"},{"key":"9326_CR47","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.4049\/jimmunol.173.5.3542","volume":"173","author":"A Cava La","year":"2004","unstructured":"La Cava A, Ebling FM, Hahn BH. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black \u00d7 New Zealand White) F1 mice suppress in vitro production of antibodies to DNA. J Immunol. 2004;173:3542\u20138.","journal-title":"J Immunol"},{"key":"9326_CR48","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/art.23609","volume":"58","author":"BH Hahn","year":"2008","unstructured":"Hahn BH, Anderson M, Le E, La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008;58:2488\u201397.","journal-title":"Arthritis Rheum"},{"key":"9326_CR49","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.4049\/jimmunol.174.6.3247","volume":"174","author":"HK Kang","year":"2005","unstructured":"Kang HK, Michaels MA, Berner BR, Datta SK. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol. 2005;174:3247\u201355.","journal-title":"J Immunol"},{"key":"9326_CR50","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.4049\/jimmunol.178.12.7849","volume":"178","author":"HK Kang","year":"2007","unstructured":"Kang HK, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol. 2007;178:7849\u201358.","journal-title":"J Immunol"},{"key":"9326_CR51","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1111\/j.1365-2567.2008.02988.x","volume":"128","author":"U Sela","year":"2008","unstructured":"Sela U, Sharabi A, Dayan M, Hershkoviz R, Mozes E. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. Immunology. 2008;128:e395\u2013405.","journal-title":"Immunology"},{"key":"9326_CR52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaut.2009.03.009","volume":"33","author":"ZM Sthoeger","year":"2009","unstructured":"Sthoeger ZM, Sharabi A, Molad Y, Asher I, Zinger H, Dayan M, et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression. J Autoimmun. 2009;33:77\u201382.","journal-title":"J Autoimmun"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-009-9326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-009-9326-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-009-9326-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T19:22:56Z","timestamp":1685128976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-009-9326-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,16]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["9326"],"URL":"https:\/\/doi.org\/10.1007\/s10875-009-9326-4","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,16]]}}}